27 October 2020
First Oncode Clinical Proof of Concept (CPoC) project now finalized
We are happy to announce that our first Oncode CPoC study - a collaboration between Oncode Investigator Jean Paul Medema (Amsterdam UMC) and clinician Henk Verheul (Radboud UMC) titled Pulsatile high dose Sunitinib as a specific drug for (a subset of) metastatic mesenchymal CRCs - is now finalized.
12 October 2020
New CPoC grant awarded: researchers and clinicians team up for study on gastroenteropancreatic neuroendocrine tumors (GEPNETs)
Oncode Institute keeps investing in bringing insights from basic science into clinical practice. With the 12th grant awarded within the CPoC programme, Oncode Investigator Roland Kanaar together with Oncode researcher Julie Nonnekens (both Erasmus MC) will team up with a group of clinicians, a physicist and pharmacist for a project focused on gastroenteropancreatic neuroendocrine tumors (GEPNETs).
29 September 2020
Oncode Facilities & Technologies will add value to your research
The goal of Oncode Institute is to translate the results of ground-breaking fundamental research into the clinic faster, in order to improve the chances of cancer patients. Investing in new technologies and facilities - which are available to all Oncode researchers - is one of the ways that Oncode wants to contribute to breakthroughs in cancer research. In this interview Jacqueline Staring, Programme Manager at Oncode Institute, discusses the facilities and technologies that are available for the Oncode research community and how they will support and accelerate oncology research.
29 September 2020
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics
Oncode Institute is proud to announce that Immagene B.V. launched this month as a private biotech company, focused on developing next-generation precision immuno-oncology therapeutics. The company announced its launch following a successful fundraise from Oncode Bridge Fund, Swanbridge Capital, and Innovatiefonds Noord Holland.
23 September 2020
Beyond Distancing: Science and Community at the Oncode Annual Scientific Meeting
The two-day Oncode Annual Scientific Meeting this month was our very first hybrid event. With a full program on both days, around 100 participants present in person each day at the Van Nelle Fabriek in Rotterdam, and more than 230 participants on average online per day, we now look back feeling both proud and relieved. Proud of an event that was successful, and relieved that this has shown that though we do need to respect the rules of social distancing, we don’t have to stay or feel apart.
22 September 2020
Oncode and ZonMw fund new Affordable Healthcare Project
Oncode’s Affordable Healthcare Programme is set up with the aim to make cancer treatment available to patients at an affordable price. Together with ZonMw, Oncode focuses on Proof of concept studies with the aim to contribute to sustainable healthcare. Oncode and ZonMw will fund new research on guided therapy in a specific type of esophageal cancer: esophageal adenocarcinoma. This clinical study aims to find out how safe and effective the addition is of stroma-targeting agent Tocilizumab to the standard of care of esophageal cancer.
In the spotlight
22 July 2020
COVID-19: updates for the Oncode research community
As an Oncode researcher, you might have questions about how we are mitigating the impact of the current COVID-19 crisis on our programmes, projects and funding. We created a Q&A with the answers these questions and plan to update this Q&A regularly.
3 September 2020
New biosensor measures activity of control enzyme MPS1
Researchers from the group of Oncode Investigator Geert Kops (Hubrecht Institute) have developed a biosensor that can precisely depict the activity of the MPS1 enzyme in living cells. MPS1 is responsible for accurate distribution of DNA during cell division; errors in this process can lead to cancer. Using the new biosensor, the researchers discovered that the MPS1 enzyme is significantly less active in colorectal cancer cells. The results were published in the scientific journal Current Biology on the 3rd of September.
18 August 2020
Pre-existing immune-resistant cancer cells identified in melanoma
Researchers at the Netherlands Cancer Institute, led by Oncode Investigator Daniel Peeper with Julia Boshuizen as first author, have discovered a cluster of tumor cells that are refractory to immunotherapy and that exists even prior to treatment. This finding, which was published in the scientific journal Nature Communications, may lead to new therapies that eliminate cancer more effectively.
22 July 2020
Masterclass: insights and best practices for managing research data
With the goal of cutting through complexity and offering clear understanding and the tools needed to handle research data management with a hands-on approach, Oncode recently organized the Research Data Management (RDM) Masterclass, part of its Open Science and FAIR Data programme. Issues such as data management planning, RDM budgeting, essentials, exposure and impact, and GDPR and informed consent were explained in context, with examples and exercises to further knowledge and understanding.
Scroll for more